PRESS RELEASE, October 15, 2018

Cinclus Pharma abstract selected "Poster of Excellence" at the UEGW conference

The Basel, Switzerland-based biotech company Cinclus Pharma AG today announced that its abstract P1152 was selected "Poster of Excellence" at the upcoming United European Gastroenterology Week, which is the largest annual meeting in Europe focused on GI-related diseases. The conference will be held in Vienna, Austria, October 20-24.

The poster presentation will be given by Kjell Andersson, CEO at Cinclus Pharma AG, and Peter Unge, CMO at Cinclus Pharma AG, on October 23 at 12.30pm – 1.30pm.

The title of Abstract P1152 is: *THE NEW P-CAB X482 WAS SAFE, TOLERABLE AND PROVIDED 24H INTRAGASTRIC CONTROL, AFTER SINGLE ORAL DOSES IN HEALTHY VOLUNTEERS.*
Authors: Kjell Andersson and Peter Unge

A link to the full abstract is available on the Cinclus Pharma website www.cinclupharma.com.

"We are honored to be selected 'Poster of Excellence' at this prestigious conference. It shows that there is a great interest for our clinical program in the scientific community," said Kjell Andersson, CEO and co-founder of Cinclus Pharma.

Earlier in 2018, Cinclus Pharma successfully concluded the first clinical Phase 1 study of its lead compound X842, for the treatment of severe erosive Gastroesophageal reflux disease (eGERD, Grades C and D).

The study showed that X842 was safe and well tolerated. Intragastric acidity, the strongly validated biomarker for healing of eGERD, was maintained above pH 4 for 24 hours after a single dose. Such level of acid control indicates that 100% healing rate of eGERD is achievable. The trial was an open label, single and multiple oral dose study in healthy volunteers receiving different dose regimens. Participants were allocated to treatment with increasing doses of X842, given as a single dose and multiple doses for five days.

Cinclus Pharma plans to initiate a clinical Phase 2 study in Europe and the US. This randomized double blind, active comparator, dose-finding study will target 300 - 400 patients with severe eGERD, with a primary objective of demonstrating superior healing rates after four weeks.

For more information, please contact:
Kjell Andersson, CEO and co-founder
Ph: +41 79 337 5081
+46 733 337 906
Email: kjell@cinclupharma.com

About GERD

Gastroesophageal reflux disease (GERD) is a digestive disorder that affects the lower esophageal sphincter (LES), the ring of muscle between the esophagus and stomach. Many people suffer from heartburn or acid regurgitation caused by GERD. About 175 million people of the adult population in US and Europe suffer from reflux disease. The global acid reflux market – worth $12-14bn - is dominated by proton-pump inhibitors (PPIs). Approximately 30% of patients with severe eGERD are unhealed after eight weeks on PPIs, and 78% of all GERD patients experience nocturnal symptoms despite PPIs - resulting in impaired quality of life. More than 20% of the all GERD patients take PPIs twice daily to overcome the incomplete symptom relief or supplement their treatment with over the counter-remedies. Despite frequent off-label prescription of high dosage PPIs, many patients still suffer from poor symptom control indicating a clear need for better drugs to treat severe or symptomatic GERD, and in particular therapies with an effect that is sustained for >24 hours.

About X842

X842 represents a novel class of drugs, Potassium Competitive Acid Blocker (P-CAB), and is a fast-acting regulator of intragastric pH by a different mechanism of action than PPIs. X842 belongs to the P-CAB class that competitively inhibits the H+, K+-ATPase in the parietal cell and thereby controls gastric acid secretion. X842 is a prodrug of linaprazan, with comprehensive data from 25 Phase I studies including more than 600 subjects. Furthermore, two Phase II studies including 2,973 patients showed that linaprazan was well tolerated, with a fast onset of action and full effect at first dose. However, linaprazan was quickly eliminated from the body and had too short duration of acid inhibition. In comparison, X842 has a longer half-life in the body, shows total control of the gastric acid production, and is tailored for patients with severe eGERD.

About Cinclus Pharma

Cinclus Pharma AG is a research-based biotech company, based in Basel, Switzerland and 100% owned by the Swedish based company Cinclus Pharma Holding AB. It develops small molecules for the treatment of gastric acid related diseases. Its lead candidate, X842, recently successfully completed a Phase I clinical trial. The Company have an experienced management team with deep knowledge in the different aspects of drug development and business development, coming from both the multinational sector as well as the Biotech sector. The management team is highly experienced in the GI area (AstraZeneca and Novartis). www.cinclusphar ma.com.